{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T03:01:25Z","timestamp":1780023685478,"version":"3.53.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Pharmaceutical Association: AOSAIKANG Hospital Pharmacy Research Project","award":["A202512"],"award-info":[{"award-number":["A202512"]}]},{"name":"the Joint Fund of the National Natural Science Foundation of China","award":["U24A20380 to L.S."],"award-info":[{"award-number":["U24A20380 to L.S."]}]},{"name":"and the Key Projects of the Jiangsu Basic Research Program","award":["BK20243061 to L.S."],"award-info":[{"award-number":["BK20243061 to L.S."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03813-x","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:57:18Z","timestamp":1776419838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The DHCQ\/HCQ metabolic ratio and CYP2C8 Genotype are associated with lipid profile improvement in systemic lupus erythematosus patients treated with hydroxychloroquine"],"prefix":"10.1186","volume":"28","author":[{"given":"Xue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou H, Ling GS, Cao X. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. J Autoimmun. 2022;132:102861.","journal-title":"J Autoimmun"},{"issue":"7","key":"3813_CR2","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.3390\/ijms24076578","volume":"24","author":"D Accapezzato","year":"2023","unstructured":"Accapezzato D, et al. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Int J Mol Sci. 2023;24(7):6578.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3813_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/0961203315603140","volume":"25","author":"S Demir","year":"2016","unstructured":"Demir S, et al. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus. 2016;25(2):177\u201384.","journal-title":"Lupus"},{"issue":"12","key":"3813_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0961203313502570","volume":"22","author":"B Parker","year":"2013","unstructured":"Parker B, Bruce I. SLE and metabolic syndrome. Lupus. 2013;22(12):1259\u201366.","journal-title":"Lupus"},{"key":"3813_CR5","doi-asserted-by":"publisher","first-page":"108876","DOI":"10.1016\/j.intimp.2022.108876","volume":"108","author":"M Lai","year":"2022","unstructured":"Lai M, et al. IL-38 in modulating hyperlipidemia and its related cardiovascular diseases. Int Immunopharmacol. 2022;108:108876.","journal-title":"Int Immunopharmacol"},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"1503434","DOI":"10.3389\/fimmu.2024.1503434","volume":"15","author":"J Xuan","year":"2024","unstructured":"Xuan J, et al. Serum lipid profile in systemic lupus erythematosus. Front Immunol. 2024;15:1503434.","journal-title":"Front Immunol"},{"key":"3813_CR7","doi-asserted-by":"publisher","first-page":"108637","DOI":"10.1016\/j.clim.2020.108637","volume":"222","author":"B Campos-L\u00f3pez","year":"2021","unstructured":"Campos-L\u00f3pez B, et al. Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: A cross-sectional study. Clin Immunol. 2021;222:108637.","journal-title":"Clin Immunol"},{"issue":"6","key":"3813_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/096120339700600610","volume":"6","author":"EF Borba","year":"1997","unstructured":"Borba EF, Bonf\u00e1 E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997;6(6):533\u20139.","journal-title":"Lupus"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12944-016-0229-0","volume":"15","author":"K Ga\u00e1l","year":"2016","unstructured":"Ga\u00e1l K, et al. High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. Lipids Health Dis. 2016;15:60.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"3813_CR10","first-page":"50","volume":"33","author":"M El Magadmi","year":"2006","unstructured":"El Magadmi M, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006;33(1):50\u20136.","journal-title":"J Rheumatol"},{"issue":"6","key":"3813_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3813_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3949\/ccjm.85a.17034","volume":"85","author":"EA Shippey","year":"2018","unstructured":"Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance. Cleve Clin J Med. 2018;85(6):459\u201367.","journal-title":"Cleve Clin J Med"},{"issue":"11","key":"3813_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/0961203312450084","volume":"21","author":"E Cairoli","year":"2012","unstructured":"Cairoli E, et al. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21(11):1178\u201382.","journal-title":"Lupus"},{"issue":"1","key":"3813_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00124743-199702000-00002","volume":"3","author":"A Kavanaugh","year":"1997","unstructured":"Kavanaugh A, et al. Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A Double-Blind, Randomized, Placebo-Controlled, Pilot Study In Patients With Systemic Lupus Erythematosus. J Clin Rheumatol. 1997;3(1):3\u20138.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"3813_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaad.2020.12.013","volume":"84","author":"JH Haugaard","year":"2021","unstructured":"Haugaard JH, et al. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. J Am Acad Dermatol. 2021;84(4):930\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3813_CR16","first-page":"1656","volume":"27","author":"SE Tett","year":"2000","unstructured":"Tett SE, et al. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis\u2013a prospective, dose ranging study. J Rheumatol. 2000;27(7):1656\u201360.","journal-title":"J Rheumatol"},{"issue":"7","key":"3813_CR17","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s10067-023-06576-x","volume":"42","author":"X Zhong","year":"2023","unstructured":"Zhong X, et al. Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration. Clin Rheumatol. 2023;42(7):1943\u201350.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"3813_CR18","doi-asserted-by":"publisher","first-page":"e000997","DOI":"10.1136\/lupus-2023-000997","volume":"10","author":"H Xie","year":"2023","unstructured":"Xie H, et al. Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE. Lupus Sci Med. 2023;10(2):e000997.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"3813_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12920-022-01171-6","volume":"15","author":"B Gao","year":"2022","unstructured":"Gao B, et al. Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions. BMC Med Genomics. 2022;15(1):23.","journal-title":"BMC Med Genomics"},{"issue":"5","key":"3813_CR20","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s10787-025-01735-9","volume":"33","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis. Inflammopharmacology. 2025;33(5):2769\u201378.","journal-title":"Inflammopharmacology"},{"issue":"14","key":"3813_CR21","first-page":"1127","volume":"21","author":"S Rendic","year":"2020","unstructured":"Rendic S, Guengerich FP. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. Curr Drug Metab. 2020;21(14):1127\u201335.","journal-title":"Curr Drug Metab"},{"key":"3813_CR22","doi-asserted-by":"publisher","first-page":"173454","DOI":"10.1016\/j.ejphar.2020.173454","volume":"886","author":"A Paniri","year":"2020","unstructured":"Paniri A, et al. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. Eur J Pharmacol. 2020;886:173454.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"3813_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231\u201369.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"3813_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/07853890.2020.1839959","volume":"53","author":"P Bansal","year":"2021","unstructured":"Bansal P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117\u201334.","journal-title":"Ann Med"},{"issue":"4","key":"3813_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/acr.22962","volume":"69","author":"J Yeon Lee","year":"2017","unstructured":"Yeon Lee J, et al. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017;69(4):536\u201342.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3813_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee JY, et al. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016;68(1):184\u201390.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"3813_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3813_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"6","key":"3813_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/ard.2006.067835","volume":"66","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau N, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):821\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3813_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ahj.2008.11.014","volume":"157","author":"V Bittner","year":"2009","unstructured":"Bittner V, et al. The triglyceride\/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women\u2019s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2009;157(3):548\u201355.","journal-title":"Am Heart J"},{"key":"3813_CR31","doi-asserted-by":"crossref","unstructured":"Salem Hareedy M, et al. CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. Drug Metab Pers Ther. 2021.","DOI":"10.1515\/dmpt-2020-0164"},{"issue":"7","key":"3813_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/chromsci\/bmaa023","volume":"58","author":"X Luo","year":"2020","unstructured":"Luo X, Peng Y, Ge W. A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients. J Chromatogr Sci. 2020;58(7):600\u20135.","journal-title":"J Chromatogr Sci"},{"issue":"7","key":"3813_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/0961203319851558","volume":"28","author":"L Geraldino-Pardilla","year":"2019","unstructured":"Geraldino-Pardilla L, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus. 2019;28(7):862\u20137.","journal-title":"Lupus"},{"issue":"7","key":"3813_CR34","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2665-9913(24)00131-0","volume":"6","author":"A Rahman","year":"2024","unstructured":"Rahman A. Systemic lupus erythematosus: managing cardiovascular risk factors. Lancet Rheumatol. 2024;6(7):e415\u20136.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"3813_CR35","doi-asserted-by":"publisher","first-page":"e2432190","DOI":"10.1001\/jamanetworkopen.2024.32190","volume":"7","author":"L Grimaldi","year":"2024","unstructured":"Grimaldi L, et al. Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus. JAMA Netw Open. 2024;7(8):e2432190.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"3813_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","volume":"33","author":"C Cunha","year":"2018","unstructured":"Cunha C, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transpl. 2018;33(9):1604\u201310.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"3813_CR37","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3899\/jrheum.151094","volume":"42","author":"N Costedoat-Chalumeau","year":"2015","unstructured":"Costedoat-Chalumeau N, V LEG, Piette JC. Routine Hydroxychloroquine Blood Concentration Measurement in Systemic Lupus Erythematosus Reaches Adulthood. J Rheumatol. 2015;42(11):1997\u20139.","journal-title":"J Rheumatol"},{"issue":"6","key":"3813_CR38","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/art.10307","volume":"46","author":"T Munster","year":"2002","unstructured":"Munster T, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3813_CR39","first-page":"e73646","volume":"16","author":"V Varaganti","year":"2024","unstructured":"Varaganti V, et al. Mechanisms Underlying Gender Influence on the Clinical Course and Immunopathogenesis of Systemic Lupus Erythematosus: An Explorative Review. Cureus. 2024;16(11):e73646.","journal-title":"Cureus"},{"issue":"1","key":"3813_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","volume":"40","author":"CE Weckerle","year":"2011","unstructured":"Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40(1):42\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3813_CR41","doi-asserted-by":"publisher","first-page":"1233883","DOI":"10.3389\/fendo.2023.1233883","volume":"14","author":"NJ Valeff","year":"2023","unstructured":"Valeff NJ, et al. Lupus and recurrent pregnancy loss: the role of female sex hormones and B cells. Front Endocrinol (Lausanne). 2023;14:1233883.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"3813_CR42","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M Jallouli","year":"2015","unstructured":"Jallouli M, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(8):2176\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3813_CR43","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan L, et al. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015;42(11):2092\u20137.","journal-title":"J Rheumatol"},{"issue":"4","key":"3813_CR44","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3899\/jrheum.150437","volume":"43","author":"L Durcan","year":"2016","unstructured":"Durcan L, et al. Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. J Rheumatol. 2016;43(4):745\u201350.","journal-title":"J Rheumatol"},{"issue":"11","key":"3813_CR45","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689\u2013723.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3813_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229\u201343.","journal-title":"Pharmacogenomics"},{"issue":"11","key":"3813_CR47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/genes11111295","volume":"11","author":"C Taylor","year":"2020","unstructured":"Taylor C, et al. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel). 2020;11(11):1295.","journal-title":"Genes (Basel)"},{"issue":"1\u20132","key":"3813_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cccn.2004.11.005","volume":"353","author":"YF Hu","year":"2005","unstructured":"Hu YF, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta. 2005;353(1\u20132):187\u201392.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3813_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2710.2008.00879.x","volume":"33","author":"SY Park","year":"2008","unstructured":"Park SY, et al. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther. 2008;33(1):61\u20135.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"3813_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1517\/14622416.6.4.357","volume":"6","author":"SJ Lee","year":"2005","unstructured":"Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005;6(4):357\u201371.","journal-title":"Pharmacogenomics"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03813-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03813-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:01:53Z","timestamp":1780020113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03813-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03813-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Ethics Committee of Nanjing Drum Tower Hospital (approval number: 2021-643-02). Participants gave informed consent to participate in the study before taking part, and the Declaration of Helsinki guidelines were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}